Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PARP inhibitor

- PMLiVE

Nothing makes sense

Evolutionary theory helps us understand and adapt to the current deal-making frenzy

- PMLiVE

Unions blast ‘negative consequences’ for Sweden of a Pfizer-AZ deal

Say proposed takeover posed an imminent risk to country's life science sector

- PMLiVE

AstraZeneca rejects ‘final offer’ from Pfizer

And US pharma company rules out hostile takeover

- PMLiVE

MPs grill Read over Pfizer’s commitments to UK

CEO faces combative parliamentary hearing over AstraZeneca bid

- PMLiVE

Amgen and AZ’s psoriasis antibody clears phase III trial

Brodalumab meets its targets in the AMAGINE-1 study

- PMLiVE

AZ starts pivotal trials of lung cancer immunotherapy

Moves MEDI4736 into phase III testing for non-small cell lung cancer

- PMLiVE

AZ circles wagons as Pfizer hints at hostile takeover

Aims for annual revenues of $45bn by 2023

- PMLiVE

FDA approves AZ’s fish oil drug

Epanova gets green light to reduce high levels of fat in the blood

- PMLiVE

Pfizer faces opposition to AZ takeover as Q1 figures disappoint

Labour leader Ed Miliband calls for public inquiry into deal

- PMLiVE

Caroline Strachan leaves AstraZeneca

She will join American Express as VP, global business consulting for EMEA

- PMLiVE

UPDATE: AZ rejects improved Pfizer bid

Continues to assert independence as Pfizer appeals to Prime Minister David Cameron

- PMLiVE

Pfizer confirms interest in AstraZeneca megamerger

Says it has twice tried to engage in merger talks with big pharma rival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links